The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

The FDA has approved Dupixent as an add-on maintenance treatment for adults with poorly controlled COPD and high counts of ...

The following is a summary of “Comparative Effectiveness of qSOFA, CURB-65, and PSI in Predicting Pneumonia Hospitalization ...

NEW YORK, May 19 (UPI) --Finding and treating people with undiagnosed asthma or chronic obstructive pulmonary disease improved their health and led ... "This is the world's first study to find people ...

Since their policy announcement in 2019, becoming smokefree is a national priority for central government who set out their ...

The National Medical Products Administration approved Dupixent as an add-on maintenance treatment for adults with ...

Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 in a broad COPD ...

China NMPA approves Sanofi & Regeneron’s Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD: Paris Monday, September 30, 2024, 11:00 Hrs [IST] The Nat ...

Global Spirometer Market is valued at approximately USD 583.2 Million in 2022 and is anticipated to grow with a healthy growth rate of more than 5.5% over the forecast period 2023-2030. Read the ...

Denham Thomas, from Hartlepool, saw his life drastically altered by Chronic Obstructive Pulmonary Disease, becoming dependent ...